

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



香港金融集團

**HONG KONG FINANCE INVESTMENT HOLDING GROUP LIMITED**  
**香港金融投資控股集團有限公司**

*(Incorporated in Bermuda with limited liability)*

**(Stock Code: 7)**

## **APPOINTMENT OF DIRECTOR OF THE COMPANY**

The board of directors is pleased to announce that Mr. Chen Mailin (“**Mr. Chen**”) has been appointed as an executive director and a managing director of the Company with effect from 16 July 2020.

Mr. Chen, aged 51, is a consultant of the Ministry of Environmental Protection and Climate Change of the Independent State of Papua New Guinea, and a visiting professor of Nanjing University of Technology. He is a former representative of the People’s Congress of Nanjing, China and a representative of the People’s Congress of Pukou District of Nanjing, where he earned “Outstanding Private Entrepreneur in Nanjing”(南京市優秀民營企業家), “Glorious Career Star”(光彩事業之星), “Nanjing Labor Model”(南京市勞動模範) and other honorary titles. He is currently the chairman of Nanjing Dingye Investment and Property Group (南京鼎業投資置業集團) and has over 20 years of experiences in decision-making and operation management in housing and urban-rural development, real estate industry, investment and capital operation.

Mr. Chen has cooperated with the mainland government by adopting a dual-development approach of industrial operation and capital operation, and completed dozens of key projects in respect of science, technology and livelihood in industrial parks, science and technology entrepreneurship parks and public communities for construction and operation through BT, PPP and other business models with a total gross floor area of 5 million square meters under joint development and operation.

Jiangsu Jinling International Medical Investment Co., Ltd. (江蘇金陵國際醫療投資有限公司), founded by Mr. Chen, is engaged in medical investment management and consulting, hospital investment management and consulting and technology transfer, and is recognized by the industry for his commitment and contribution to the production and operation of medical and environmental protection equipment.

Mr. Chen also invested in the establishment of the National Private GLP Innovative Drug Clinical Safety Evaluation Center (創新藥物臨床安全性評價中心) and was successfully listed on the “New Third Board”(「新三板」) in the PRC, which its high-technology has expanded its business cooperation to countries such as the United States, Canada and the European Union. Mr. Chen also has property and hotel investment, development and operation businesses in Hong Kong and Canada.

Save as disclosed above, as at the date of this announcement, Mr. Chen (i) does not have any relationship with any directors, senior management or substantial or controlling shareholders of the Company; (ii) does not have any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (the “SFO”); and (iii) did not hold any other positions with the Company and other members of the Group, nor any other directorships in other public companies, the securities of which are listed on any securities market in Hong Kong or overseas in the last three years up to the date of this announcement.

Mr. Chen will enter into a service contract with the Company for an initial term of three years commencing from 16 July 2020, pursuant to which Mr. Chen shall hold office until the next annual general meeting of the Company and thereafter shall be subject to retirement by rotation and re-election at the Company’s annual general meeting in accordance with the bye-laws of the Company. Mr. Chen is entitled to a director’s fee of HK\$1,200,000 per annum which is determined by arm’s length negotiation between Mr. Chen and the Company and with reference to his duties and responsibilities. The amount of the remuneration has been approved by the board of directors and the remuneration committee of the Company.

Mr. Chen holds 200,000,000 ordinary shares of the Company, representing 5% of the aggregate nominal value of the issued share capital of the Company. Save as disclosed herein, there is no other information to be disclosed pursuant to the requirements of Rule 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and there are no other matters relating to the appointment of Mr. Chen that need to be brought to the attention of the shareholders of the Company.

The board of directors of the Hong Kong Finance Investment Group would like to extend its welcome to Mr. Chen to become a shareholder of the Group and join the board of directors. With his strong capabilities and successful experiences, we believe that he will be able to bring new impetus to the development of the Hong Kong Finance Investment Group.

By order of the board of directors  
**Hong Kong Finance Investment Holding Group Limited**  
**Dr. Hui Chi Ming, G.B.S., J.P.**  
*Chairman*

Hong Kong, 16 July 2020

*As at the date of this announcement, the Honorary Chairman and Senior Consultant of the Company is Dr. Yukio Hatoyama; the senior consultants of the Company comprise Dr. Wang Tao, Mr. Fu Chenyu and Mr. Lalaharisaina Joelivalerien; the board of directors comprises eight executive Directors, namely, Dr. Hui Chi Ming, G.B.S., J.P., Mr. Neil Bush, Mr. Chen Mailin, Mr. Cao Yu, Mr. Xu Jun Jia, Mr. Lam Kwok Hing, M.H., J.P., Mr. Nam Kwok Lun and Mr. Hui Ngok Lun; and four independent non-executive Directors, namely, Mr. Ngan Kam Biu, Stanford, Mr. Tam Chak Chi, Mr. Ma Kin Ling and Mr. Chow Kin Wing.*